Hampel looks to the future of the Alzheimer space and sees promise, especially since there’s transfertilization from other advanced science fields in medicine like oncology, diabetes research and rheumatology.
Harald Hampel, MD, PhD, MA, MSc
Advertisement
Articles by Harald Hampel, MD, PhD, MA, MSc
The phase IIb/III study is scheduled to initiate enrollment of approximately 450 patients, randomized 1:1:1 to 2 different ANAVEX 2-73 doses or placebo.
ANAVEX 2-73 is being studied as the first potential precision medicine biomarker-guided, targeted therapeutic in Alzheimer disease.
Advertisement
Latest Updated Articles
FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer DiseasePublished: August 29th 2025 | Updated: September 2nd 2025
Indirect Comparison Study Hints at Lower ARIA and ICH-Related Mortality Risk in Lecanemab Over DonanemabPublished: July 28th 2025 | Updated: July 30th 2025
Observed Differences in PIRA Definition Call for More Standardized Agreement on TermPublished: May 14th 2025 | Updated: May 16th 2025
Serum Neurofilament Light Chain Limited in Predicting MOGAD Attacks but Correlates With Attack SeverityPublished: May 12th 2025 | Updated: May 13th 2025
- FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion CountsPublished: March 4th 2025 | Updated: March 19th 2025
Advertisement
Advertisement
Trending on NeurologyLive
1
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
2
EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits
3
Evolving Responsibilities of Vice Chairs in Neurology Leadership: Mud Alvi, MD
4
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
5
